Verve Therapeutics Inc (NASDAQ: VERV) is -61.41% lower on its value in year-to-date trading and has touched a low of $4.30 and a high of $20.12 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VERV stock was last observed hovering at around $5.51 in the last trading session, with the day’s loss setting it -0.13%.
Currently trading at $5.38, the stock is -4.02% and -10.13% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.42 million and changing -2.36% at the moment leaves the stock -40.36% off its SMA200. VERV registered -58.13% loss for a year compared to 6-month loss of -59.79%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 6.32% gain in the last 1 month and extending the period to 3 months gives it a 4.87%, and is -4.78% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.75% over the week and 8.92% over the month.
Verve Therapeutics Inc (VERV) has around 255 employees, a market worth around $455.26M and $20.65M in sales. Profit margin for the company is -933.02%. Distance from 52-week low is 24.97% and -73.26% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.67%).
The EPS is expected to grow by 17.45% this year
239.0 institutions hold shares in Verve Therapeutics Inc (VERV), with institutional investors hold 99.62% of the company’s shares. The shares outstanding are 81.97M, and float is at 62.47M with Short Float at 26.14%. Institutions hold 91.96% of the Float.
The top institutional shareholder in the company is ALPHABET INC. with over 12.35 million shares valued at $60.26 million. The investor’s holdings represent 14.8546 of the VERV Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.62 million shares valued at $32.31 million to account for 7.9632 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.26 million shares representing 6.3314 and valued at over $25.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 5.4476 of the shares totaling 4.53 million with a market value of $22.1 million.
Verve Therapeutics Inc (VERV) Insider Activity
The most recent transaction is an insider purchase by Ashe Andrew D.,. SEC filings show that Ashe Andrew D. bought 76,000 shares of the company’s common stock on May 14 ’24 at a price of $6.26 per share for a total of $0.48 million. Following the purchase, the insider now owns 0.34 million shares.
Verve Therapeutics Inc disclosed in a document filed with the SEC on Apr 02 ’24 that Nickerson Joan (Chief Administrative Officer) sold a total of 1,514 shares of the company’s common stock. The trade occurred on Apr 02 ’24 and was made at $8.24 per share for $12475.0. Following the transaction, the insider now directly holds 8659.0 shares of the VERV stock.
Still, SEC filings show that on Nov 29 ’23, Dorval Allison (Chief Financial Officer) disposed off 554 shares at an average price of $11.45 for $6343.0. The insider now directly holds 4,060 shares of Verve Therapeutics Inc (VERV).
